Otwarty dostęp

Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 – a single centre report


Zacytuj

1. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol 2006; 8: 27-37.10.1215/S1522851705000323Search in Google Scholar

2. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011; 105: 1414-8.10.1038/bjc.2011.357Search in Google Scholar

3. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 1994; 74: 1383-97.10.1002/1097-0142(19940815)74:4<1383::AID-CNCR2820740432>3.0.CO;2-1Search in Google Scholar

4. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993; 119: 1093-104.10.7326/0003-4819-119-11-199312010-00007Search in Google Scholar

5. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988; 68: 835-53.10.3171/jns.1988.68.6.0835Search in Google Scholar

6. Kachanov DY, Dobrenkov KV, Shamanskaya TV, Abdullaev RT, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.10.2478/v10019-007-0037-2Search in Google Scholar

7. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 1999; 43: 199-201.10.1023/A:1006290032052Search in Google Scholar

8. Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med 2008; 132: 1830-44.10.5858/132.11.1830Search in Google Scholar

9. Herrlinger U, Schabet M, Clemens M, Kortmann RD, Petersen D, Will BE, et al. Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand 1998; 97: 257-64.10.1111/j.1600-0404.1998.tb00647.xSearch in Google Scholar

10. Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000; 92: 261-6.10.3171/jns.2000.92.2.0261Search in Google Scholar

11. Linnert M, Iversen HK, Gehl J. Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy. Radiol Oncol 2012; 46: 271-8.10.2478/v10019-012-0042-ySearch in Google Scholar

12. Tezcan Y, Koc M. 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors. Radiol Oncol 2011; 45: 213-9.10.2478/v10019-011-0019-2Search in Google Scholar

13. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859-63.10.1200/JCO.1998.16.3.859Search in Google Scholar

14. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiation therapy: preliminary results. Neurology 1996; 46: 1757-9.10.1212/WNL.46.6.1757Search in Google Scholar

15. Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, et al. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 1998; 4: 110-24.Search in Google Scholar

16. Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf I, Helmstaedter C, et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 2001; 71: 118-22.10.1136/jnnp.71.1.118Search in Google Scholar

17. Blay JY. Primary cerebral non-Hodgkin lymphoma in non-immunocompromised subjects. Bull Cancer 1997; 84: 976-80.Search in Google Scholar

18. Pech IV, Peterson K, Cairncross JG. Chemotherapy for brain tumors. Oncology (Williston Park) 1998; 12: 537-53.Search in Google Scholar

19. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000; 11: 927-37.10.1023/A:1008376412784Search in Google Scholar

20. Stanic K, Kovac V. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana. Radiol Oncol 2010; 44: 213-9.10.2478/v10019-010-0038-4Search in Google Scholar

21. Horvat M, Jezersek Novakovic B. Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma. Radiol Oncol 2010; 44: 232-8.10.2478/v10019-010-0044-6Search in Google Scholar

22. Gregoric B, Zadnik V, Jezersek Novakovic B. The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. Radiol Oncol 2012; 46: 153-9.10.2478/v10019-012-0002-6Search in Google Scholar

23. O’Neill BP, O’Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy. Int J Radiat Oncol Biol Phys 1995; 33: 663-73.10.1016/0360-3016(95)00207-FSearch in Google Scholar

24. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996; 14: 556-64.10.1200/JCO.1996.14.2.5568636771Search in Google Scholar

25. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58: 1513-20.10.1212/WNL.58.10.151312034789Search in Google Scholar

26. Shibamoto Y, Ogino H, Suzuki G, Takemoto M, Araki N, Isobe K, et al. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004. Neuro Oncol 2008; 10: 560-8.10.1215/15228517-2008-028266622918559969Search in Google Scholar

27. Joerger M, Huitema AD, Krähenbühl S, Schellens JH, Cerny T, Reni M, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102: 673-7.10.1038/sj.bjc.6605559283757420125159Search in Google Scholar

28. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz MJ, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-43.10.1200/JCO.2005.13.52415955902Search in Google Scholar

29. Uhm JE, Kim KH, Yi SY, Chang MH, Park KW, Kong DS, et al. A retrospective study to compare two methotrexate-based ragimens for primary central nervous system lymphoma. Leuk Lymphoma 2009; 50: 1110-8.10.1080/1042819090296477619557631Search in Google Scholar

30. Lim T, Kim SJ, Kim K, Lee Ji, Lim do H, Lee DJ, et al. Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. Ann Hematol 2011; 90: 1391-8.10.1007/s00277-011-1225-0321036321479535Search in Google Scholar

31. Herrlinger U, Schabet M, Bitzer M, Petersen D, Krauseneck P. Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 1999; 43: 219-26.10.1023/A:1006298201101Search in Google Scholar

32. Shibamoto Y, Sasai K, Oya N, Hiraoka M. Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study. J Neurooncol 1999; 42: 161-7.10.1023/A:1006106530795Search in Google Scholar

33. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 1994; 81: 188-95.10.3171/jns.1994.81.2.01888027800Search in Google Scholar

34. O′Brien PC, Roos, DE, Liew KH, Trotter GE, Barton MB, Walker QJ, et al. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group. Med J Aust 1996; 165: 424-7.Search in Google Scholar

35. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512-20.10.1016/S0140-6736(09)61416-1Search in Google Scholar

36. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high-dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23: 9-17.10.1016/0360-3016(92)90538-SSearch in Google Scholar

37. Laack NN, Ballman KV, Brown PB, O’Neill BP; North Central Cancer Treatment Group. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys 2006; 65: 1429-39.10.1016/j.ijrobp.2006.03.061Search in Google Scholar

38. Laperriere NJ, Cerezo L, Milosevic MF, Wong CS, Patterson B, Panzarella T. Primary lymphoma of brain: results of management of a modern cohort with radiation therapy. Radiother Oncol 1997; 43: 247-52.10.1016/S0167-8140(97)00074-1Search in Google Scholar

39. Brada M, Hjiyiannakis D, Hines F, Traish D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 1998; 40: 1157-62.10.1016/S0360-3016(98)00002-9Search in Google Scholar

40. O’Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000; 18: 519-26.10.1200/JCO.2000.18.3.51910653867Search in Google Scholar

41. Niemiec M, Głogowski M, Tyc-Szczepaniak D, Wierzchowski M, Kępka L. Characteristics of long-term survivors of brain metastases from lung cancer. Rep Pract Oncol Radiother 2011; 16: 49-53.10.1016/j.rpor.2011.01.002386316524376956Search in Google Scholar

eISSN:
1581-3207
ISSN:
1318-2099
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Medicine, Clinical Medicine, Radiology, Internal Medicine, Haematology, Oncology